Jennifer Viera - Enanta Pharmaceuticals Senior Communications
| ENTA Stock | USD 8.83 0.27 3.15% |
Executive
Jennifer Viera is Senior Communications of Enanta Pharmaceuticals
| Address | 500 Arsenal Street, Watertown, MA, United States, 02472 |
| Phone | 617 607 0800 |
| Web | https://www.enanta.com |
Enanta Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1718) % which means that it has lost $0.1718 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5964) %, meaning that it created substantial loss on money invested by shareholders. Enanta Pharmaceuticals' management efficiency ratios could be used to measure how well Enanta Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.29. The current year's Return On Capital Employed is expected to grow to -0.36. At present, Enanta Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 5.6 M, whereas Total Assets are forecasted to decline to about 333.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD FACC | Design Therapeutics | 55 | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Christopher Dinsmore | Kronos Bio | 57 | |
| Thomas Leggett | Stoke Therapeutics | 47 | |
| Courtney Solberg | C4 Therapeutics | N/A | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Carlos Bais | Inhibrx | N/A | |
| Charles Lin | Kronos Bio | 39 | |
| Allison JD | Kronos Bio | 41 | |
| Ashraf Amanullah | Inhibrx | 56 | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Shamim MS | Stoke Therapeutics | 64 | |
| Michael MD | Century Therapeutics | 53 | |
| Rose Weldon | Cullinan Oncology LLC | N/A | |
| Bonne MBA | Inhibrx | 47 | |
| Matthew JD | Lyell Immunopharma | 48 | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| John Moore | Edgewise Therapeutics | 60 | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
| Josep Garcia | Inhibrx | N/A | |
Management Performance
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.17 |
Enanta Pharmaceuticals Leadership Team
Elected by the shareholders, the Enanta Pharmaceuticals' board of directors comprises two types of representatives: Enanta Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enanta. The board's role is to monitor Enanta Pharmaceuticals' management team and ensure that shareholders' interests are well served. Enanta Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enanta Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jay Luly, CEO and President and Director | ||
| Scott MD, Senior Officer | ||
| Nathalie MD, Consultant | ||
| Jennifer Viera, Senior Communications | ||
| Nathaniel JD, General VP | ||
| Tara Kieffer, Senior Development | ||
| Brendan Luu, Senior Development | ||
| Matthew JD, Chief Officer | ||
| Paul Mellett, CFO and Sr. VP of Fin. and Admin. | ||
| Yat Or, Chief Scientific Officer and Sr. VP of RandD | ||
| Scott Rottinghaus, VP Officer |
Enanta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enanta Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.60) % | ||||
| Operating Margin | (1.35) % | ||||
| Current Valuation | (11.34 M) | ||||
| Shares Outstanding | 21.19 M | ||||
| Shares Owned By Insiders | 6.00 % | ||||
| Shares Owned By Institutions | 94.00 % | ||||
| Number Of Shares Shorted | 3.38 M | ||||
| Price To Earning | 366.13 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (5.65) | Revenue Per Share 3.407 | Quarterly Revenue Growth (0.05) | Return On Assets (0.17) |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.